BTHE - Boston Therapeutics, Inc.
| Previous Close | 0.0081 |
| Open | 0.0081 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0081 - 0.0081 |
| 52 Week Range | 0.0081 - 0.0500 |
| Volume | 1,000 |
| Avg. Volume | 45,895 |
| Market Cap | 900,161 |
| Beta (3Y Monthly) | -0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0180 |
| Earnings Date | Mar 25, 2016 - Mar 29, 2016 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.12 |
- GlobeNewswire
Boston Therapeutics Ph 2 Study Achieves Full Enrollment
Boston Therapeutics (BTHE) is again pleased to announce full enrollment of the BTI320 Ph 2 double-blind, placebo-controlled, multicenter trial. With the recent inclusion of Miami Dade Medical Research Institute in June and IOWA Diabetes in Feb, recruitment of patients reached full enrollment on Aug 1, 2019(n=65).
- GlobeNewswire
Boston Therapeutics Announces Official Sales and Marketing Launch of Sugardown® in Asia
Boston Therapeutics Inc. (the “Company” or “BTI”) (BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches the initial sales and marketing of cross border products in China via one of the largest e-commerce platform: Tao Bao. Newly manufactured Sugardown® chewable tablets have been received in China in Jan 2019 to support the launching of product by an elite e-marketing group (JD Jin Long) in China. A total of 5,000 units have been allocated for this initial sales launch.
- GlobeNewswire
Boston Therapeutics Announces Marketing of Sugardown® in Asia
LAWRENCE, Mass., Dec. 13, 2018 -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel.
- GlobeNewswire
Boston Therapeutics Announces Initiation of Sales of Sugardown® in Asia
Boston Therapeutics, Inc. (the “Company” or “BTI”) (BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches an initial sale of product in Myanmar and test market in China. Newly manufactured Sugardown® chewable tablets have been received in China and are due for shipment and sale to China Mainland in the next two weeks. This may be a substantial contribution of up to $310,000 to support the Company from its Asian Partner.